Breaking News, Promotions & Moves

Emmes Group Appoints Chief Commercial Officer of Emmes Biopharma

Germaine Gross has spent over 30 years in life sciences and 15 years leading CRO Business Development efforts.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Germaine Gross.

Emmes Group, a specialty tech and AI-enabled global contract research organization (CRO), has appointed Germaine Gross as Chief Commercial Officer of Emmes Biopharma.

With more than 30 years in life sciences and 15 years leading CRO Business Development efforts, Gross will spearhead the next phase of growth in Emmes Biopharma’s business portfolio. Reporting directly to Emmes Group Chief Executive Officer Sastry Chilukuri and serving on the company’s Executive Management Committee, she will play a critical role in deepening Emmes’ partnerships and delivering transformative solutions for biopharma-sponsored clinical trials.

“Germaine’s impressive track record of leadership, industry expertise, and proven ability to cultivate lasting partnerships makes her the perfect fit for this role,” said Sastry Chilukuri, Chief Executive Officer. “Her appointment comes at a pivotal moment as we redefine how biopharma clinical research is conducted by leveraging AI, advanced technology, and operational excellence. We’re confident that Germaine’s leadership will amplify our ability to deliver exceptional value to our biopharma partners.”

Experience

Gross has held leadership roles at industry-leading organizations such as ICON, PRA Health Sciences, and INC Research, where she successfully developed and expanded business portfolios. Prior to joining Emmes, she led the Asia Pacific Commercial Team at ICON.

With deep expertise in mergers and acquisitions, commercial operations, and strategic alliances, Gross has a proven ability to foster strong partnerships and implement innovative solutions. Her track record aligns seamlessly with Emmes Group’s vision for transformative growth.

Gross said: “Emmes has an extraordinary legacy of innovation and scientific excellence across its 47-year history. Combining this legacy with cutting-edge technology and AI to enable faster, higher quality clinical research has the potential to transform the industry. I look forward to working with the talented team at Emmes Group to expand our reach, enhance client partnerships, and help shape the future of biopharma clinical trials.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics